The care of patients with NSCLC requires a range of resources in a variety of settings in the real world. eCollection 2023. Eligible patients are adults aged 18 years and older with continuous enrollment in the HIRD for at least 6 months before their first claim for a prescription for a study antimicrobial. Data Integration to Improve Real-world Health Outcomes Research for Non doi: 10.1200/CCI.18.00156. 2013 Feb;11(1):27-43. doi: 10.1007/s40258-012-0001-1. With the current availability of a wide range of newer, more effective systemic therapies, including several novel biologic agents, the use of diverse provider, institutional, and registry databases is increasingly necessary to evaluate outcomes due to the gaps in administrative claims data alone [32-35]. Judith STEPHENSON | Principal Scientist | Research profile HealthCore. jValues <10 have not been reported for patient confidentiality. Parlett LE, Beachler DC, Lanes S, Hoover RN, Cook MB. Researchers using the HIRD and the Boston Health Economics platform now have the ability to create a code definition library, identify specific population groups, specify baseline and outcome variables, conduct statistical analyses, and produce reports all in an easy-to-use interface, said Mark Cziraky, vice president of research for HealthCore. NSCLC and other forms of cancer are increasingly being managed like chronic diseases with a broad range of increasingly effective treatments. Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. f2L medications of interest included atezolizumab, docetaxel, erlotinib, nivolumab, pembrolizumab, pemetrexed, or ramucirumab. Home - hyperCORE International Clarke CL, Feigelson HS. Nadler E, Espirito JL, Pavilack M, Boyd M, Vergara-Silva A, Fernandes A. Monitoring Editor: Deborah Vollmer Dahlke, Reviewed by Thomas Burke and Negin Hesam-Shariati. This is a critical component and driver of Carelons goal of solving complex challenges in healthcare. Frontiers | Validation of a Case-Finding Algorithm for Identifying Enriched study types often combine secondary data sources, along with primary data collection via chart reviews and other forms of physician or opt-in patient data collection, including patient-reported outcomes. iThese are the final sample sizes for the 2 cohorts of interest. and find answers faster and more cost-effectively to questions, providers, include more detailed resource use and cost of care analysis, Your email address will not be published. Find out whats going on right here, right now. The mean duration of 1L therapy was 128 (median 90) days; 56.84% (1122/1974) switched to 2L therapy with a gap 90 days and 43.16% (852/1974) had a gap of >90 days before initiating 2L. Among the 407 patients with MR data, 59.2% (241/407) were former smokers, 16.5% (67/407) were current smokers, 14.3% (58/407) were never smokers, and 10.1% (41/407) had no documentation. Among the 269 patients who received radiation therapy after the initial diagnosis of NSCLC, 46.1% (124/269) patients received radiation therapy as a palliative treatment. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners. These cookies do not store any personal information. MeSH We describe challenges and learnings from the data integration process, and the benefits of the integrated data set, which includes a richer set of clinical and outcome data to supplement the utilization metrics available in administrative claims. Jkel A, Plested M, Dharamshi K, Modha R, Bridge S, Johns A. Appl Health Econ Health Policy. The study will be implemented in the population included in the HealthCore Integrated Research Database (HIRD). Bethesda, MD 20894, Web Policies Fair Billing Practice. information on nearly 60 million individuals from multiple health plans Bradley Hammill. All cancer stages were included in the analyses. To learn more about Houston KA, Henley SJ, Li J, White MC, Richards TB. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. A real-world study on characteristics, treatments and outcomes in US Today we have nearly three decades of experience supporting this need with a powerful ecosystem of expertise, data, and relationships. 2010 Mar;159(3):462-470.e1. Asan O, Nattinger AB, Gurses AP, Tyszka JT, Yen TWF. IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. Data linkages between patient-powered research - Oxford Academic Gathering the Patient Perspective | Carelon Research Our research capabilities include extensive experience in HEOR, Late Phase, Safety and Epidemiology and Survey-Based research services and solutions with our work designed to improve quality, safety and affordability in health care. For patients with third- and/or fourth-line therapy (n=731 and 265, respectively), platinum-based regimens were used most frequently (418/731, 57.2% of third-line patients and 139/265, 52.5% of fourth-line patients), and 21.6% (158/731) of third-line patients and 20.4% (54/265) of fourth-line patients also used immunotherapy. Leveraging linkage of cohort studies with administrative claims data to identify individuals with cancer. HealthCore, Inc. is the wholly-owned, independently operating health outcomes research subsidiary of Anthem, Inc. We work with life sciences companies, payers and providers, and government and academic organizations to provide real-world evidence in support of a wide variety of health care decisions. Access to the HealthCore Integrated Research Database, known as the HIRD, contains integrated longitudinal medical and pharmacy claims data for more than 48 million individuals and lab result data for more than 17 million individuals. Access to the HealthCore Integrated Research Database, known as the To address the possibility that exclusions may have been extensive and led to biased estimates of completion rates, we conducted a claims database analysis in the HealthCore Integrated Research Database SM to evaluate the proportion of rotavirus vaccinated infants who completed the 3 dose series of RV5. information to health care decision makers. Validation of a case-finding algorithm for identifying patients with Non-small Cell Lung Cancer (NSCLC) in administrative claims databases. largest commercially insured population databases in the United States Patients were required to receive 1 of the following 2L therapies alone or in combination: atezolizumab, docetaxel, erlotinib, nivolumab, pembrolizumab, pemetrexed, or ramucirumab. The main analysis cohort included patients with claims data and data from at least one additional data source (CCQP or MR). Wilson J, Bock A. official website and that any information you provide is encrypted Part of the reason is that although RCTs have internal validity, which is essential for safety and efficacy determinations, results from clinical studies may have limited external validity. for more than 48 million individuals and lab result data for more than Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. IQVIA is committed to enhancing evidence generation with the goal of advancing patient health and clinical outcomes.. Health economics & outcomes research: Identifies the real-world value of biomedical products and leverages those insights to advance actionable information for stakeholders. Cancer statistics, 2020. large, rich patient population using the most widely-adopted real-world For example, a diagnosis code on a medical claim (eg, for secondary malignancies) does not guarantee the presence of a disease. statistical analyses, and produce reports all in an easy-to-use Value Health. Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Sands J, Santana-Davila R, Williams CC, Hoffmann KG, Hughes M. NCCN guidelines insights: small cell lung cancer, version 2.2018. RESOUNDS (Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer) was a retrospective, observational cohort study that integrated data from 4 sources: administrative claims from the HealthCore Integrated Research Database (HIRD), clinical data from a quality initiative called the Cancer Care Quality Program (CCQP), clinical data extracted from patients MRs obtained from treating providers, and all-cause mortality data from the Death Master File of the US Social Security Administration. Ke X, Navaratnam P, Sasane R, Lawrence DFE, Friedman HS, Tulsi BB, Vollmer T. Determinants of high cost in multiple sclerosis patients: a claims and chart review study. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval. A patient was considered to be on the same line of therapy until new agents were added (except for maintenance and platinum agent switching), a gap of >90 days between treatments, end of follow-up, or (for 2L and higher) discontinuation. Brahmer J, Reckamp KL, Baas P, Crin L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arn Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus docetaxel in advanced squamous-cell nonsmall-cell lung cancer. RWE studies incorporate innovative scientific methods with dynamic data from sources such as electronic medical records, pharmacy and medical claims, laboratory and genomics records, and patient-reported outcomes. Int J Appl Basic Med Res. "Harness technology for a healthier world. Wilmington, DE, Carelon Research, formerly HealthCore, is now a member of the Carelon family of companies under Elevance Health. An official website of the United States government. HIRD - HealthCore Integrated Research Database - All Acronyms Administrative healthcare claims and laboratory results data from the US HealthCore Integrated Research Database sm were evaluated for patients with COPD initiating tiotropium/olodaterol versus LABA/ICS treatment (January 2013-March 2019). Would you like email updates of new search results? -. Carelon Research partners with life sciences companies, government agencies, academic institutions, and other key healthcare stakeholders who rely on evidence to guide decisions. 2023 Apr 8;15:251-267. doi: 10.2147/CEOR.S401003. 1 HealthCore, Inc., 123 S. Justison Street, Suite 200, Wilmington, DE, 19801-5134, USA. As RWE grows and gains value, especially for pragmatic clinical trials (PCTs), the traditional gold standard of a randomized clinical trial (RCT) is facing major hurdles: low recruitment rates, small patient populations, long durations, and high costs. 2019 doi: 10.17226/25352. Medication use among patients with Crohn's disease or ulcerative Careers, Unable to load your collection due to an error. Katkade VB, Sanders KN, Zou KH. Treatment patterns and clinical outcomes among metastatic non-small-cell lung cancerpatients treated in the community practice setting. By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes. You are about to exit for another IQVIA country or region specific website. This subset of the original set of therapies listed in the protocol [26] was selected based on treatment guidelines and observed frequency of use during the study period, to ensure sufficient sample sizes to evaluate treatment patterns. HealthCore Announces First-Time Direct Access to its Research Data for The .gov means its official. Patients diagnosed with lung cancer who initiated 2L therapy between November 01, 2015, and April 13, 2018, were identified in the HIRD and CCQP data. We accessed administrative claims data from the HealthCore Integrated Research Database, which contains longitudinal claims from 8 health insurance plans in all regions of the United States. Clinical research: Designs and executes clinical trials from start-up to closeout to drive needed therapies and meaningful outcomes. Data source and population. The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale. perform clinical record review and validation, and design and implement HealthCore Announces First-Time Direct Access to its Research Data Nonsmall cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases [23]. Patients were aged at least 40 years with a diagnosis of COPD (but not asthma) at cohort entry. 2017 Oct 30;15(1):193. doi: 10.1186/s12916-017-0954-x. See Full PDF Download PDF. It was designed to simulate a prospective observational study by identifying patients upfront within large preexisting databases and then following them within the data set to examine outcomes. The HIRD provides researchers with improved healthcare insights and decision making through an easy-to-use software interface by allowing them to answer questions about how their products fit into treatment patterns, whether their products impact the correct population and whether their targeted clinical trial group will lead to meaningful and actionable findings. Treating physician specialty based on claims listed oncologists for 67.52% (1482/2195) of the main analysis population and for 30.7% (286/931) of the claims-only sample; this difference is by design as only patients whose 2L-prescribing providers were listed as oncologists were included in the MR phase. To learn more, visit www.iqvia.com. 2.1 Data Source. Baseline was defined as the 6 months before the index date (start of 2L therapy). Comparing Biologic Cost Per Treated Patient Across - Springer Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety and quality. Once obtained and screened, clinical information was abstracted from each record by trained health information management technicians using a standardized form. JCO Clin Cancer Inform. Most HealthCore de-identified claims and clinical data have been incorporated into the IQVIA PharMetrics Plus data source, resulting in a substantial patient volume increase. This website uses cookies to improve your experience. HealthCore Inc 1 healthcore integrated research database hird 1 Healthcore Integrated Research Database Hird, supplied by HealthCore Inc, used in various techniques. Indianapolis, IN, Assessing bias in administrative database studies of RotaTeq vaccine Patients with lung cancer who initiated second-line (2L) therapy between November 01, 2015, and April 13, 2018, were identified in the claims and CCQP data. The integration of data from disparate sources could help alleviate data insufficiency in real-world studies and compensate for the inadequacies of single data sources and short-duration, small sample size studies while improving the utility of data for research. Results: Data on 265 patients (100 abatacept, 165 TNFis) were collected. The integrated data set is also used to describe patient demographics, clinical characteristics, treatment patterns, and mortality rates. Khozin S, Abernethy AP, Nussbaum NC, Zhi J, Curtis MD, Tucker M, Lee SE, Light DE, Gossai A, Sorg RA, Torres AZ, Patel P, Blumenthal GM, Pazdur R. Oncologist. Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. We work with life sciences companies, government agencies, payors, and collaborators on a broad range of research services focused on informing key decision makers. This will All patients identified in the CCQP data were also included in the HIRD sample; patients who appeared in the HIRD but not the CCQP were retained. IQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Takahashi Y, Nishida Y, Asai S. Utilization of health care databases for pharmacoepidemiology. Holistic View of Autografting Patients by Percentage of Total Body Surface Area Burned: Medical Record Abstraction Integrated with Administrative Claims. HealthCore is now Carelon Research. Li Y, Appius A, Pattipaka T, Feyereislova A, Cassidy A, Ganti AK. As a member of the Carelon family of companies, and a wholly owned, independently operating subsidiary of Elevance Health, we have an opportunity to amplify the impact of research results. Similarly, tumor growth and progression information is collected in various formats and levels of detail outside of a clinical trial setting. Methods: This retrospective study used administrative claims data from the HealthCore Integrated Research Database (HIRD SM) for adults with rheumatoid arthritis, psoriatic arthritis, psoriasis, and/or ankylosing spondylitis who . Data from each source were accumulated in 3 consecutive waves to continuously build the database. and transmitted securely. Comparing Biologic Cost Per Treated Patient Across Indications - PubMed "Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. National Library of Medicine The HIRD provides researchers with improved healthcare insights and decision making through an easy-to-use . The Super Network of Premier Research Sites Learn More Who is hyperCORE International?hyperCORE International is a super network of highly experienced and awarded clinical trial sites working together to accelerate and advance clinical research. Ultimately, this unique combination of the HIRD and Boston Health Economics Instant Health Data Platform will enable our clients to improve insights and decision making in healthcare.. dThis was based on the Death Master File data from the US Social Security Administration. Proceedings published by the National Academies of Sciences, Engineering, and Medicine chronicle the presentations and discussions at a workshop, symposium, or other event convened by the National Academies. population groups, specify baseline and outcome variables, conduct PMC Overcoming data integration and completeness challenges will allow better informed decision making by all stakeholders of the health care system. Researchers using the HIRD and the Boston Health Economics platform now Approximately 47.14% (997/2115) of patients fulfilled regulatory and operational requirements for their MRs to be requested from their 2L-prescribing providers; for 54.5% (543/997) of those, the records were obtained. The mean duration of 2L therapy was 169 (median 121) days; this variable was right-censored due to loss of follow-up. The typical limitations of claims data also apply. Keywords: Methods: We conducted a retrospective cohort study of IBD patients in the HealthCore Integrated Research Database (HIRD (TM)) between January 2004 and January 2011 to determine rates of AEs in patients with mild and moderate to severe IBD. An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise. disciplines to generate evidence on how medical advances can improve TheFreeDictionary HIRD (redirected from Healthcore Integrated Research Database) Copyright 1988-2018 AcronymFinder.com, All rights reserved. Objective: and transmitted securely. The integration of clinical data from different sources such as MRs [8], disease registries, or quality initiatives with large administrative claims repositories has been shown to increase the volume and quality of available data [9-12]. Data integration resulted in a main analysis cohort of 2195 patients with NSCLC; 2106 patients had CCQP and 407 patients had MR data. Patient sample sizes available for analysis diminish when multiple data sources are required. Classifying Stage IV lung cancer from health care claims: a comparison of multiple analytic approaches. Voluntary patient participation allows linkage to other supported data sources, allowing a more complete view into the patient healthcare experience. This innovative research collaboration will focus specifically on real world studies such as external comparators, pragmatic trials, and enriched studies. Clopidogrel use and clinical events after drug-eluting stent Federal government websites often end in .gov or .mil. Health Economics. Health and Medicine Division. BHE is an independent health analytics company with over two decades of Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium variety of health care decisions. Methods: This retrospective cohort study queried the HealthCore Integrated Research Database to identify patients 18 years with 2 diagnoses of MF-CTCL (ICD-9-CM code 202.1x, 202.2x) between . Univariate statistics including means, SDs, and medians for continuous variables and relative frequencies and percentages for categorical variables were reported. Were committed to supporting the need for evidence generation and research collaboration in the marketplace, and delivering the expertise, unparalleled data, relationships, and evidence-generation capabilities long valued by our partners and clients in life sciences, government, and academia. Accuracy of medicare claim-based algorithm to detect breast, prostate, or lung cancer bone metastases. The HIRD is a longitudinal medical and pharmacy claims database from health plan members across each region of the US. Careers. United States. This site needs JavaScript to work properly. healthcare insights and decision making through an easy-to-use software Clopidogrel Use and Clinical Events After Drug-Eluting Stent IQVIA is a global leader in protecting individual patient privacy. Survey-Based research services and solutions with our work designed to Data collected from patients in surveys, interviews, and other patient-centered research activities can be linked with claims data, clinical data, laboratory data, and prospective data, to provide a robust, industry-unmatched research response. https://creativecommons.org/licenses/by/4.0/, https://linkinghub.elsevier.com/retrieve/pii/S1098-3015(10)60470-6, http://www.ijabmr.org/article.asp?issn=2229-516X;year=2015;volume=5;issue=2;spage=82;epage=82;aulast=Mahajan, https://ascopubs.org/doi/10.1200/CCI.18.00156?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed, http://europepmc.org/abstract/MED/15492029, http://europepmc.org/abstract/MED/30938759, https://www.optum.com/content/dam/optum/resources/whitePapers/Benefits-of-using-both-claims-and-EMR-data-in-HC-analysis-WhitePaper-ACS.pdf, http://europepmc.org/abstract/MED/29334524, http://europepmc.org/abstract/MED/30829831, http://europepmc.org/abstract/MED/27195308, https://ascopubs.org/doi/10.1200/CCI.17.00163?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed, https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html, http://europepmc.org/abstract/MED/25172266, https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1011-0, https://www.researchprotocols.org/2017/10/e195/, https://ascopubs.org/doi/10.1200/CCI.17.00118?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed, http://europepmc.org/abstract/MED/24520142, http://europepmc.org/abstract/MED/26412456, https://www.futuremedicine.com/doi/10.2217/cer-2018-0066?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed, https://healthpolicy.duke.edu/sites/default/files/2020-08/rwe_white_paper_2017.09.06.pdf, https://dx.plos.org/10.1371/journal.pone.0178420, https://linkinghub.elsevier.com/retrieve/pii/S1525-7304(18)30099-8, https://dx.plos.org/10.1371/journal.pone.0175679, https://ro-journal.biomedcentral.com/articles/10.1186/s13014-019-1222-3, https://dx.plos.org/10.1371/journal.pone.0209709, https://linkinghub.elsevier.com/retrieve/pii/S1525-7304(18)30021-4, https://www.futuremedicine.com/doi/10.2217/fon-2018-0939?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed, https://www.futuremedicine.com/doi/10.2217/fon-2019-0348?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed, Step 1: Patients with nonsmall cell lung cancer, Step 1: Patients with lung cancer claim before start of first-line therapy, Step 2: From step B1, patients with 2L therapy, Step 1: From A2 and B2, unique patients with 2L therapy, Step 4: Not used (target had been met previously), Step F: Claims-only cohort (patients with claims data only, no CCQP or MR data), HealthCore Integrated Research Database (claims), Performance status (Eastern Cooperative Oncology Group), (Quan-Charlson Comorbidity Index, secondary cancers), Age at second-line therapy initiation (years), mean (SD), Hilar, lobar, and/or (sub)segmental nodes, Duration of time (days) between initial lung cancer diagnosis and 1L treatment, mean (SD), Both curative and palliative (separate instances), Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer.
Carnival Cruise Motown Party, My Friend Has A Girlfriend, Articles H